{"transactions":[{"id":1425032,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-08-22T22:01:51.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001610717-24-000436","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000436/form4.xml","form_type":"4"}},{"id":1425031,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-08-22T22:01:51.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":4181,"price":1.2291,"value":5138.8671,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 64,802 restricted stock units."}],"balance_after":119056,"source":{"system":"sec-edgar","filing":"0001610717-24-000436","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000436/form4.xml","form_type":"4"}},{"id":1425030,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-08-22T22:01:51.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,927 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 64,802 restricted stock units."}],"balance_after":123237,"source":{"system":"sec-edgar","filing":"0001610717-24-000436","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000436/form4.xml","form_type":"4"}},{"id":1564604,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-21T20:36:46.000Z","date":"2024-03-19","kind":"sale","planned":false,"acquired":false,"shares":6562,"price":2.0855,"value":13685.051,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 64,802 restricted stock units."}],"balance_after":110060,"source":{"system":"sec-edgar","filing":"0001610717-24-000175","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000175/form4.xml","form_type":"4"}},{"id":1675002,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-01-20T01:40:22.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001610717-24-000033","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000033/form4.xml","form_type":"4"}},{"id":1675001,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-20T01:40:22.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":140000,"derivative":{"exercise_price":1.68,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001610717-24-000033","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000033/form4.xml","form_type":"4"}},{"id":1675000,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-20T01:40:22.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 82,205 RSUs."}],"balance_after":116622,"source":{"system":"sec-edgar","filing":"0001610717-24-000033","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000033/form4.xml","form_type":"4"}},{"id":1700664,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-12-22T21:12:57.000Z","date":"2023-12-20","kind":"sale","planned":false,"acquired":false,"shares":4077,"price":1.3805,"value":5628.2985,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 52,205 restricted stock units."}],"balance_after":86622,"source":{"system":"sec-edgar","filing":"0001610717-23-000421","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071723000421/form4.xml","form_type":"4"}},{"id":1704435,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2023-12-20T00:56:09.000Z","date":"2023-12-17","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."}],"balance_after":11250,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001610717-23-000410","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071723000410/form4.xml","form_type":"4"}},{"id":1704434,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-12-20T00:56:09.000Z","date":"2023-12-17","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 52,205 restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,310 shares and 1,760 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023 and November 30, 2023, respectively."}],"balance_after":90699,"source":{"system":"sec-edgar","filing":"0001610717-23-000410","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071723000410/form4.xml","form_type":"4"}},{"id":1774528,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-09-22T23:15:12.000Z","date":"2023-09-22","kind":"sale","planned":false,"acquired":false,"shares":4119,"price":1.3003,"value":5355.9357,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 52,205 restricted stock units."}],"balance_after":76379,"source":{"system":"sec-edgar","filing":"0001610717-23-000298","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071723000298/form4.xml","form_type":"4"}},{"id":1774527,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-09-22T23:15:12.000Z","date":"2023-09-20","kind":"grant","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Performance Stock Units (\"PSUs\") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 52,205 restricted stock units."}],"balance_after":80498,"source":{"system":"sec-edgar","filing":"0001610717-23-000298","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071723000298/form4.xml","form_type":"4"}},{"id":1944187,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-20T22:43:29.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":1477,"price":1.9792,"value":2923.2784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 52,205 restricted stock units."}],"balance_after":69248,"source":{"system":"sec-edgar","filing":"0001140361-23-012615","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036123012615/form4.xml","form_type":"4"}},{"id":2030311,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2023-02-06T21:49:44.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001567619-23-001929","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761923001929/doc1.xml","form_type":"4"}},{"id":2030310,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-06T21:49:44.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":100000,"derivative":{"exercise_price":2.59,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001567619-23-001929","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761923001929/doc1.xml","form_type":"4"}},{"id":2030309,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-02-06T21:49:44.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 56,274 RSUs."}],"balance_after":70725,"source":{"system":"sec-edgar","filing":"0001567619-23-001929","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761923001929/doc1.xml","form_type":"4"}},{"id":2186633,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2022-08-12T21:00:43.000Z","date":"2022-08-10","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001567619-22-015866","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761922015866/doc1.xml","form_type":"4"}},{"id":2186632,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-12T21:00:43.000Z","date":"2022-08-10","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":135000,"derivative":{"exercise_price":1.59,"expiration_date":"2032-08-09","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001567619-22-015866","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761922015866/doc1.xml","form_type":"4"}},{"id":2203772,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-07-21T20:11:13.000Z","date":"2022-07-20","kind":"sale","acquired":false,"shares":4206,"price":1.4222,"value":5981.7732,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 16,274 restricted stock units."}],"balance_after":30725,"source":{"system":"sec-edgar","filing":"0001567619-22-014300","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761922014300/doc1.xml","form_type":"4"}},{"id":2203771,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-07-21T20:11:13.000Z","date":"2022-07-19","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Performance Stock Units (\"PSUs\") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 16,274 restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the adjusted total which includes the purchase of 5,040 shares under the Cytomx Therapeutics Employee Stock Purchase Plan on May 31, 2022."}],"balance_after":34931,"source":{"system":"sec-edgar","filing":"0001567619-22-014300","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761922014300/doc1.xml","form_type":"4"}}]}